Premedication after grade 1 infusion reaction

Vantrexa · Metastatic NSCLC

MI-2026-0085RoutineClosedWithin SLAEscalatedSafety

RARachel AdeyemiMSL, Oncology (UK & Ireland)

Restricted — potential adverse event

Access limited to Medical Information and Safety roles. Details are captured minimally and routed to pharmacovigilance per SOP-PV-014. AI features are disabled for this record (PRD §27.7).

Received: 23 Mar 2026, 17:28 UTC
Channel: Web portal
Requestor type: HCP
Country / region / team: United States · North America · MI Americas
Category: Safety
Response type: Custom response
Owner: RARachel Adeyemi
Due: 28 Mar 2026, 17:28 UTC
Responded: 27 Mar 2026, 20:28 UTC
Quality review: Passed
Related insight: —
Related standard response: None matched (topic-keyword match)

Workflow

12-stage inquiry workflow (PRD §16). Advancing records an audit event.

Received
Triage
Assigned
In progress
Escalated
Draft response
Medical review
Quality review
Sent
Follow-up required
11Closed
12Archived

Current stageClosedDemo action — not persisted

SLA

Routine: 120 h target · Routine 120 h / Urgent 48 h / Critical 24 h

SLA hours

120

Elapsed

99 h

to response

Remaining

21 h

83%

Timeline

23 Mar 2026, 17:28 UTC
Received via Web portal
HCP · United States
23 Mar 2026, 17:28 UTC
Triage and assignment
Urgency Routine · assigned to MI Americas
23 Mar 2026, 17:28 UTC
Escalated
Safety flag — routed to pharmacovigilance
27 Mar 2026, 20:28 UTC
Response sent
Custom response · quality review passed
28 Mar 2026, 17:28 UTC
SLA due (120 h)

Draft response

Restricted record

AI suggestion disabled — safety-flagged inquiries are not interpreted by AI (PRD §27.7).

Draft response

Audit history

No audit events for this record

Create, update, approve and export events appear here with user, timestamp, previous and new values.

Data lineage: MI inquiry platform (IRMS, INT-05) · received 23 Mar 2026 · hourly sync.